Migraine Treatment Options: Compare Top Medications & Benefits
Migraine Drugs Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of qualitative and quantitative research methods, it offers comprehensive reports that help clients navigate complex market landscapes, drive strategic growth, and seize new opportunities in an ever-evolving global market.
Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):–
The global migraine drugs market reached USnbsp;10.90 billion in 2023 and is expected to reach USnbsp;23.70 billion by 2031, growing at a CAGR of 10.3% during the forecast period 2024-2031.
List of the Key Players in the Migraine Drugs Market:
Amgen Inc, Tonix Pharmaceuticals, Teva Pharmaceuticals, Eli Lilly and Company, AbbVie Inc, Pfizer Inc, Lundbeck, Impel Pharmaceuticals Inc, Currax Pharmaceuticals, Endo Pharmaceuticals Inc
Industry Development:
In January 2024, Akums Drugs and Pharmaceuticals Ltd introduced Lasmiditan, a selective serotonin receptor agonist designed for migraine relief. It works by blocking pain signals to the brain and reducing nerve inflammation. The tablet, containing lasmiditan hemisuccinate, targets the 5-HT1F receptor to provide effective migraine relief. The medication has been approved by both the Drug Controller General of India (DCGI) and its U.S. counterpart.
In April 2024, the National Institute for Health and Care Excellence (NICE) approved Atogepant (Aquipta) for migraine prevention in England. This follows the UK-wide approval of Rimegepant for migraine prevention and its treatment authorization in England, Scotland, and Wales.
Growth Forecast Projected:
The Global Migraine Drugs Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.
Research Process:
Both primary and secondary data sources have been used in the global Migraine Drugs Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
Segment Covered in the Migraine Drugs Market:
By Drug Class: NSAIDs, Acetaminophen, CGRP Monoclonal Antibodies, CGRP Small Molecule Antagonists, Acetylcholine Inhibitors/ neurotoxins, Triptans, Antidepressants, Ergot alkaloids, Others
By Route of Administration: Oral, Injectable, Others
By Age Group: Pediatric, Adult, Geriatric
By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
English
Arabic
Français
Español
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian